Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

• Main Authors: Xinyu Yan (Author), Shouyue Zhang (Author), Yun Deng (Author), Peiqi Wang (Author), Qianqian Hou (Author), Heng Xu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large indi...